Table 2.
Comparison of HIV/HCV-coinfected patients with FIB-4 <1.45 and ≥1.45 who underwent transient elastography
| Patient characteristics | All patients (n = 114) |
FIB-4 <1.45 (n = 57) |
FIB-4 ≥1.45 (n = 57) |
P-value |
|---|---|---|---|---|
| Epidemiological characteristics | ||||
| Sex | ||||
| Male | 68% (77/114) | 72% (41/57) | 63% (36/57) | 0.317 |
| Female | 33% (37/114) | 28% (16/57) | 37% (21/57) | |
| Age | 43.5 (17.7) | 34.2 (16.1) | 49.4 (11.0) | <0.001 |
| Transmission | ||||
| MSM | 7% (8/114) | 5% (3/57) | 9% (5/57) | 0.648 |
| IVDU | 71% (81/114) | 72% (41/57) | 70% (40/57) | |
| Heterosexual | 17% (19/114) | 19% (11/57) | 14% (8/57) | |
| Others | 5% (6/114) | 4% (2/57) | 7% (4/57) | |
| Laboratory parameters | ||||
| Hemoglobin (g dl−1) | 13.8 (2.85) | 13.9 (2.32) | 13.8 (2.62) | 0.375 |
| Platelet count (G l−1) | 200 ± 74.62 | 241 ± 63.8 | 158 ± 60.7 | <0.001 |
| White blood cell count (G l−1) | 6.54 ± 2.67 | 7.28 ± 2.11 | 5.79 ± 2.97 | 0.003 |
| Prothrombin time (%) | 93.0 (33.5) | 96.0 (37.5) | 91.5 (39.3) | 0.167 |
| Albumin (g dl−1) | 42.9 ± 4.66 | 43.5 ± 4.41 | 42.3 ± 4.86 | 0.166 |
| Creatinine (mg dl−1) | 0.84 (0.24) | 0.80 (0.24) | 0.88 (0.23) | 0.205 |
| Bilirubin (mg dl−1) | 0.50 (0.46) | 0.43 (0.34) | 0.53 (0.46) | 0.011 |
| AST (U l−1) | 43.5 (27.3) | 37.0 (21.0) | 51.0 (31.0) | <0.001 |
| ALT (U l−1) | 41.0 (28.5) | 40.0 (22.5) | 44.0 (39.5) | 0.451 |
| GGT (U l−1) | 76.0 (86.0) | 62.5 (75.8) | 90.0 (80.0) | 0.002 |
| HIV infection parameters | ||||
| CD4+ T‑lymphocyte count (cells μl −1 ) | 523 ± 272 | 628 ± 279 | 421 ± 224 | <0.001 |
| HIV-RNA <50 copies ml −1 | 74% (84/113) | 75% (42/56) | 74% (42/57) | 0.873 |
| HIV-RNA <400 copies ml −1 | 89% (100/113) | 86% (48/56) | 91% (78/57) | 0.358 |
| cART | 95% (108/114) | 93% (53/57) | 97% (55/57) | 0.679 |
| PI | 44% (48/108) | 45% (24/53) | 44% (24/55) | 0.863 |
| N(t)RTI | 94% (102/108) | 96% (51/53) | 93% (51/55) | 0.679 |
| NNRTI | 21% (23/108) | 21% (11/53) | 22% (12/55) | 0.893 |
| II/EI | 35% (38/108) | 36% (19/53) | 35% (19/55) | 0.887 |
| HCV infection parameters | ||||
| HCV-RNA (log IU ml −1 ) | 6.00 (1.07) | 5.80 (1.23) | 6.24 (0.99) | 0.72 |
| HCV genotype | 94% (107/114) | 93% (53/57) | 95% (54/57) | – |
| 1 | 56% (60/107) | 58% (31/53) | 54% (29/54) | 0.145 |
| 2 | 0% (0/107) | 0% (0/53) | 0% (0/54) | |
| 3 | 32% (34/107) | 25% (13/53) | 39% (21/54) | |
| 4 | 12% (13/107) | 17% (9/53) | 7% (4/54) | |
| Liver stiffness | ||||
| F0/F1 (<7.1 kPa) | 42% (48/114) | 60% (34/57) | 25% (14/57) | <0.001 |
| F2 (≥7.1 and <9.5 kPa) | 31% (35/114) | 23% (13/57) | 39% (22/57) | 0.068 |
| F3 (≥9.5 and <12.5 kPa) | 7% (8/114) | 7% (4/57) | 7% (4/57) | 1 |
| F4 (≥12.5 kPa) | 20% (23/114) | 11% (6/57) | 30% (17/57) | 0.010 |
| Significant liver fibrosis (≥7.1 kPa) | 58% (66/114) | 40% (23/57) | 75% (43/57) | <0.001 |
| Advanced liver fibrosis (≥9.5 kPa) | 27% (31/114) | 18% (10/57) | 37% (21/57) | 0.021 |
ALT alanine transaminase, AST aspartate transaminase, cART combined antiretroviral therapy, EI entry inhibitors, GGT gamma-glutamyl transpeptidase, GT genotype, HCV hepatitis C virus, HIV human immunodeficiency virus, II integrase inhibitors, IVDU intravenous drug abuse, MSM men who have sex with men, NNRTI non-nucleoside reverse-transcriptase inhibitors, N(t)RTIs nucleos(t)idic reverse transcriptase inhibitors, PI protease inhibitor